Vorinostat resistance management

Vorinostat (Vorinostat) is a histone deacetylase (HDAC) inhibitor indicated for the treatment of cutaneous manifestations in patients with progressive, persistent, or relapsed cutaneous T-cell lymphoma (CTCL) after prior systemic therapy. Drug resistance means that after long-term use of vorinostat, tumor cells gradually become resistant to it. In order to deal with the problem of vorinostat resistance, adjustments can be made under the guidance of a doctor.

Combining vorinostat with other anticancer drugs with different mechanisms of action may be able to enhance efficacy and overcome resistance. This can act on tumor cells simultaneously through multiple pathways and reduce the resistance of tumor cells to vorinostat. After treatment with vorinostat, the use of this drug can be suspended and other anticancer drugs with similar mechanisms of action can be used for treatment. This rotation strategy prevents tumor cells from developing long-lasting resistance to vorinostat. Under the guidance of your doctor, the dose or frequency of administration of vorinostat can be adjusted. Increasing drug dosage or frequency may improve the killing effect on tumor cells and thereby overcome drug resistance. Develop an individualized treatment plan based on the patient's genotypic and phenotypic characteristics.

The original drug of vorinostat is not currently on the market in China, and therefore cannot be included in the national medical insurance coverage. There is an American version of the original vorinostat drug overseas. The price of each box of 100mg*120 tablets may be around 100,000 yuan (the price may fluctuate due to the exchange rate). The price is very expensive. There is currently no generic version of vorinostat on the market. For more drug information and specific prices, please consult Yaode Medical Consultants.